EN-2642 / Enosi, Danuo Science Group - LARVOL DELTA

Enosi Therapeutics to Present at the ENA 2022 Symposium on Molecular Targets and Cancer Therapeutics in Barcelona (PRNewswire) - "Enosi Therapeutics...has announced that Enosi CEO and CSO, Dr. H. Michael Shepard, will be presenting the company's preclinical work in a presentation...at the ENA 2022 Symposium being held in Barcelona October 26-28, 2022....EN-2642 is an affinity matured EGFR-Fc: HER3:Fc ligand trap and binds 9 of the 11 growth factors which activate the HER family. These growth factors participate in the progression of many diseases, including solid cancers and rheumatoid arthritis, which are characterized by hyperproliferative cells, hypoxia, angiogenesis, and inflammation."

Preclinical • Oncology • Solid Tumor